A new Executive Order in the U.S. aims to ease the path to market for products that use synthetic biology or genome editing. Emily Marden explains the thinking behind the announcement and its efforts to streamline the current U.S. framework for biotech.
Chris Fanelli explains what the U.S. Food and Drug Administration’s new draft guidance on remote regulatory assessments means for site inspections in the future, and how manufacturing facilities can prepare for requests for Remote Regulatory Assessments.
https://goodlifesci.sidley.com/wp-content/uploads/sites/6/2022/03/sidleyLogo-e1643922598198.png00Christopher A. Fanellihttps://goodlifesci.sidley.com/wp-content/uploads/sites/6/2022/03/sidleyLogo-e1643922598198.pngChristopher A. Fanelli2022-11-10 10:04:432025-09-26 16:11:51Remote Regulatory Assessment Oversight Tools Piloted During the COVID-19 Pandemic Are Here to Stay
Resources
Upcoming Events
Archives
Categories
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Biden Administration Moves to Boost the Bioeconomy
A new Executive Order in the U.S. aims to ease the path to market for products that use synthetic biology or genome editing. Emily Marden explains the thinking behind the announcement and its efforts to streamline the current U.S. framework for biotech.
Emily Marden
San Francisco
emarden@sidley.com
Remote Regulatory Assessment Oversight Tools Piloted During the COVID-19 Pandemic Are Here to Stay
Chris Fanelli explains what the U.S. Food and Drug Administration’s new draft guidance on remote regulatory assessments means for site inspections in the future, and how manufacturing facilities can prepare for requests for Remote Regulatory Assessments.
Christopher A. Fanelli
Washington, D.C.
cfanelli@sidley.com
Resources
Upcoming Events
Archives
Categories